Navigation Links
Repligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference Monday, November 10th, 4:55 p.m. EST
Date:11/3/2008

WALTHAM, Mass., Nov. 3 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) announced today that the Company President and Chief Executive Officer, Walter C. Herlihy, Ph.D., will present at the Rodman & Renshaw 10th Annual Healthcare Conference on Monday, November 10th, 2008 at 4:55 p.m. EST at the New York Palace Hotel, 455 Madison Avenue, New York, NY.

A live audio-webcast of the presentation will be available via Repligen's website at http://www.repligen.com and will be archived for 30 days following the presentation.

About Repligen Corporation

Repligen Corporation is a biopharmaceutical company focused on the development of novel therapeutics for diseases that affect the central nervous system. In addition, we are the world's leading supplier of recombinant Protein A, the sales of which partially fund the advancement of our development pipeline while supporting our financial stability. Repligen's corporate headquarters are located at 41 Seyon Street, Building #1, Suite 100, Waltham, MA 02453. Additional information may be requested from http://www.repligen.com.

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding current or future financial performance and positio
'/>"/>

SOURCE Repligen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT
2. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
3. Repligen Receives Research Grants to Support Friedreichs Ataxia Development Program
4. Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
5. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
6. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
7. Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
8. RainDance Technologies to Present Sequence Enrichment Using Droplet-Based Microfluidics Workshop at ASHG 2008
9. SCOLR Pharma, Inc. to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
10. Nile Therapeutics to Present at Two Upcoming Investor Conferences
11. Arno Therapeutics to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... TX (PRWEB) , ... July 29, 2015 , ... ... designer, manufacturer and supplier, announces the launch of their 2nd generation cell therapy ... the current miniPOD CT, but it also represents a new POD® design. ...
(Date:7/29/2015)... 2015  AmnioChor Inc., an early stage biotech startup ... to announce that the Musculoskeletal Transplant Foundation of ... in their seed round of development of the proprietary ... AmnioChor,s technology allows cryopreservation of the ... cells living within those tissues. Amnion is a well-established ...
(Date:7/29/2015)...  Indivior PLC (LON: INDV) today announced that the ... accepted and received Priority Review by the U.S. Food ... overdose. This naloxone nasal spray comes as a pre-filled ... into the nasal mucosa. 1 The device has ... be better equipped to help an opioid overdose victim. ...
(Date:7/29/2015)... QUEBEC CITY , July 29, 2015 /PRNewswire/ ... (the "Company") today announced it has selected an optimized ... important milestone in the development of a new ... The MAPK pathway represents a prime target for ... significant antitumor activities and survival benefits for B-Raf ...
Breaking Biology Technology:G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 2G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 3The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 4Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 5Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3
... Hyman Jr. Professor of Chemistry, was recently awarded ... the synthesis of a wide range of nanoscale ... of those materials, and the development of hierarchical ... the use of nanoscale materials in nanoelectronics, nanocomputing, ...
... Mich., Jan. 23, 2012  A recent Van Andel Research Institute ... the molecular structure and function of an essential plant hormone ... and might ultimately lead to the development of new drugs ... builds on earlier work by the same team of investigators ...
... 23, 2012 Aethlon Medical, Inc. ... filtration devices to address infectious disease, cancer and ... established an Extracorporeal Therapy Scientific Advisory Board to ... other therapies developed from the Aethlon ADAPT™ system.  ...
Cached Biology Technology:Van Andel Research Institute Study Provides New Details of Fundamental Cellular Process 2Aethlon Medical Establishes Extracorporeal Therapy Scientific Advisory Board 2Aethlon Medical Establishes Extracorporeal Therapy Scientific Advisory Board 3Aethlon Medical Establishes Extracorporeal Therapy Scientific Advisory Board 4Aethlon Medical Establishes Extracorporeal Therapy Scientific Advisory Board 5Aethlon Medical Establishes Extracorporeal Therapy Scientific Advisory Board 6Aethlon Medical Establishes Extracorporeal Therapy Scientific Advisory Board 7
(Date:7/2/2015)... DUBLIN , June 25, 2015 ... the addition of the "Next Generation Biometrics Market ... to 2020" report to their offering. ... $24.4 Billion by 2020, at a CAGR of 17.9% ... is the leading application for the market. Safran ...
(Date:6/30/2015)... -- To bolster its efforts and commitment to fighting cyber ... addition of two new team members. ... David Raviv will act as head of strategic alliances. ... providing the most secure solutions for the enterprise market. ... Technologies, a provider of security and management products, which was ...
(Date:6/29/2015)... Research and Markets( http://www.researchandmarkets.com/research/zj7h4f/latin_america ... America Biomedical Sensors Market - Growth, Trends & Forecasts ... Latin America Biomedical Sensors market is estimated at $0.65 ... the period 2014-2020 The near future will ... formulation of each individual. These sensors can be set ...
Breaking Biology News(10 mins):Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3Latin America Biomedical Sensors Market Report 2015-2020 2
... to diagnose infectious diseases are urgently needed in ... an American Academy of Microbiology colloquium, "Bringing the ... Resource Limited Settings," describes the challenges inherent in ... areas of the world where they are needed ...
... (SACRAMENTO, Calif.) A team of UC Davis investigators has ... in the development of prostate cancer. The mutation of the ... disease progression, but until now has never been shown to ... avenues for diagnosing and treating the disease. The ...
... As one of the few probiotics with medical food ... a collection of more than 80 studies that have demonstrated ... and an ileal pouch. Ulcerative colitis patients, in particular, have ... their prescription drug regimen. One particular study shows that the ...
Cached Biology News:Report addresses challenges in implementing new diagnostic tests where they are needed most 2UC Davis scientists find new role for P53 genetic mutation -- initiation of prostate cancer 2By adding VSL#3 probiotic to traditional therapies UC patients can improve remission rates 2
... The FailSafe™ PCR System is the ... the first time and every time. It ... regardless of the source or the property ... EPICENTRE's FailSafe™ PCR Enzyme Mix, a unique ...
...
... G|2 Doublestain System is a high-sensitivity ... kit. The kit is intended for ... detection of two different antigens within ... with suitably diluted rabbit and mouse ...
Anti-TNKS2 Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: ELISA, Western Blot...
Biology Products: